Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration

Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration Letters Figure. Bilateral Choroidal Detachment in a 73-Year-Old Man After Infusion of the CD38 Monoclonal Antibody, Daratumumab A Ultrawide-field funduscopic view B Funduscopic reexamination A, Ultrawide-field funduscopic view scan showing bilateral choroidal detachment (arrowheads). B, Funduscopic reexamination showing complete remission of choroidal detachment. events, there are no reports to date of choroidal detachment 3. Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors [published online January 23, 2019]. Retina. associated with infusion of daratumumab and in other simi- doi:10.1097/IAE.0000000000002451 lar monoclonal antibodies in this class. As the patient discon- tinued further daratumumab treatment, it is unclear whether methylprednisolone contributed to the improvement or if this COMMENT & RESPONSE was because of resolution over time. Oral Tyrosine Kinase Inhibitors for Neovascular Peter K. Rasmussen, MD, PhD Age-Related Macular Degeneration Jens F. Kiilgaard, MD, PhD To the Editor We recently reported a phase I dose-escalation Morten Salomo, MD, DMSc, PhD study of the oral tyrosine kinase inhibitor vorolanib (previ- ously known as X-82 [Tyrogenex]), which was used as a treat- Author Affiliations: Department of Ophthalmology, Rigshospitalet Glostrup, ment for neovascular age-related macular degeneration University Hospital Copenhagen, Copenhagen, Denmark (Rasmussen, (AMD). We have since been made http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration

Loading next page...
 
/lp/american-medical-association/oral-tyrosine-kinase-inhibitors-for-neovascular-age-related-macular-WPFaLXkM0h
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2019.0861
Publisher site
See Article on Publisher Site

Abstract

Letters Figure. Bilateral Choroidal Detachment in a 73-Year-Old Man After Infusion of the CD38 Monoclonal Antibody, Daratumumab A Ultrawide-field funduscopic view B Funduscopic reexamination A, Ultrawide-field funduscopic view scan showing bilateral choroidal detachment (arrowheads). B, Funduscopic reexamination showing complete remission of choroidal detachment. events, there are no reports to date of choroidal detachment 3. Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors [published online January 23, 2019]. Retina. associated with infusion of daratumumab and in other simi- doi:10.1097/IAE.0000000000002451 lar monoclonal antibodies in this class. As the patient discon- tinued further daratumumab treatment, it is unclear whether methylprednisolone contributed to the improvement or if this COMMENT & RESPONSE was because of resolution over time. Oral Tyrosine Kinase Inhibitors for Neovascular Peter K. Rasmussen, MD, PhD Age-Related Macular Degeneration Jens F. Kiilgaard, MD, PhD To the Editor We recently reported a phase I dose-escalation Morten Salomo, MD, DMSc, PhD study of the oral tyrosine kinase inhibitor vorolanib (previ- ously known as X-82 [Tyrogenex]), which was used as a treat- Author Affiliations: Department of Ophthalmology, Rigshospitalet Glostrup, ment for neovascular age-related macular degeneration University Hospital Copenhagen, Copenhagen, Denmark (Rasmussen, (AMD). We have since been made

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jul 2, 2019

References